<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275833</url>
  </required_header>
  <id_info>
    <org_study_id>RESTORE AV</org_study_id>
    <nct_id>NCT01275833</nct_id>
  </id_info>
  <brief_title>Restoration of Atrioventricular Synchrony Trial</brief_title>
  <acronym>RESTORE-AV</acronym>
  <official_title>Restoration of Atrioventricular Synchrony Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to observe the effects of restoring atrioventricular (AV)
      synchrony in subjects with prolonged PR intervals. This will be assessed both acutely and
      chronically using echocardiographic and functional measurements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as above.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult subject recruitment
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Range Finding of Functional and Hemodynamic Changes Using Echocardiographic Determined Measures.</measure>
    <time_frame>6 months</time_frame>
    <description>Echocardiographic measures will include, but not be limited to, left ventricular volumes, left ventricular diameters, and ejection fraction.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>First Degree AV Block</condition>
  <arm_group>
    <arm_group_label>Device programming modifies AV timing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DDD-40-BiV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device programming allows intrinsic AV timing.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>VVI-40-RV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy-defibrillator</intervention_name>
    <description>Device programming that modifies AV timing</description>
    <arm_group_label>Device programming modifies AV timing</arm_group_label>
    <other_name>First degree AV block</other_name>
    <other_name>Long PR interval</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet current indications for an implantable cardioverter-defibrillator (ICD) implant
             with:

          -  QRS width &lt; 120 msec

          -  Left ventricular ejection fraction (LVEF) &lt; 35% (no more than 180 days prior to
             enrollment)

          -  NYHA functional class II/III

          -  Optimal pharmacological heart failure therapy

          -  PR interval &gt;/= 230 msec

          -  Ability to tolerate protocol required programming

          -  Access to a telephone line compatible with the LATITUDEÂ® Communicator

          -  Subjects in sinus rhythm at the time of the baseline visit and who are expected to
             remain in sinus rhythm for the duration of the study

          -  Age 18 or above, or of legal age to give informed consent specific to state and
             national law

          -  Willing and capable of providing informed consent, undergoing a device implant,
             participating in all testing associated with this clinical investigation at an
             approved clinical investigational center and return to the investigational center at
             the intervals defined by this protocol

        Exclusion Criteria:

          -  Previously placed pacemaker, ICD, or CRT device

          -  Inability or refusal to sign the Informed Consent Form

          -  Documented life expectancy of less than 12 months or expected to undergo heart
             transplant within the next 12 months

          -  Have tricuspid valve disease or who are likely to receive a mechanical tricuspid valve
             during the course of the clinical investigation

          -  Inability or refusal to comply with the follow-up schedule

          -  Have a neuromuscular, orthopedic, or other noncardiac condition that prevents subject
             from normal unsupported walking for the six minute hall walk test

          -  Have surgically uncorrected primary valvular heart disease

          -  Second or third degree atrioventricular block (AVB)

          -  Permanent or persistent atrial tachyarrhythmia that is refractory to all therapies

          -  Have had cardiac surgery, percutaneous coronary intervention, or myocardial infarction
             within 3 months of signing consent or who are likely to undergo a cardiac surgery or
             procedure in the foreseeable future

          -  Enrolled in any concurrent study unless written approval has been obtained from Boston
             Scientific or The Integra Group

          -  Women who are pregnant or plan to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Olshansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Day, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>April 10, 2017</results_first_submitted>
  <results_first_submitted_qc>June 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2017</results_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable ICD</keyword>
  <keyword>First Degree AV block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Device Programming That Modifies AV Timing</title>
          <description>Cardiac resynchronization therapy-defibrillator: Device programming that modifies AV timing</description>
        </group>
        <group group_id="P2">
          <title>Device Programming That Allows Intrinsic AV Timing.</title>
          <description>Cardiac resynchronization therapy-defibrillator: Device programming that does not modifies AV timing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Device Programming Modifies AV Timing</title>
          <description>DDD-40-BiV
Cardiac resynchronization therapy-defibrillator: Device programming that modifies AV timing</description>
        </group>
        <group group_id="B2">
          <title>Device Programming Allows Intrinsic AV Timing.</title>
          <description>VVI-40-RV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Range Finding of Functional and Hemodynamic Changes Using Echocardiographic Determined Measures.</title>
        <description>Echocardiographic measures will include, but not be limited to, left ventricular volumes, left ventricular diameters, and ejection fraction.</description>
        <time_frame>6 months</time_frame>
        <population>The study was terminated early: long PR intervals are relatively rare in this population, and it would take an inordinately long time to enroll sufficient patients. Because of the early termination of the study, no data was analyzed since the primary objective is underpowered.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Programming That Modifies AV Timing</title>
            <description>Cardiac resynchronization therapy-defibrillator: Device programming that modifies AV timing</description>
          </group>
          <group group_id="O2">
            <title>Device Programming That Allows Intrinsic AV Timing.</title>
            <description>Cardiac resynchronization therapy-defibrillator: Device programming that does not modifies AV timing</description>
          </group>
        </group_list>
        <measure>
          <title>Range Finding of Functional and Hemodynamic Changes Using Echocardiographic Determined Measures.</title>
          <description>Echocardiographic measures will include, but not be limited to, left ventricular volumes, left ventricular diameters, and ejection fraction.</description>
          <population>The study was terminated early: long PR intervals are relatively rare in this population, and it would take an inordinately long time to enroll sufficient patients. Because of the early termination of the study, no data was analyzed since the primary objective is underpowered.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported as of ICF signature, and were supposed to be collected until the 12-month follow-up visit. However, the study was terminated early (1 subject had a 6-month follow-up visit, the second subject did not have a 6-month follw-up visit).</time_frame>
      <desc>An adverse event (AE) was defined as any undesirable clinical occurrence in a subject. This can be a subject complaint, change in health status, or product issue. An adverse event will not be reported if the underlying condition existed at enrollment and continued unchanged thereafter unless the event worsened considerably and required additional medical or pharmacological treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Device Programming That Modifies AV Timing</title>
          <description>Cardiac resynchronization therapy-defibrillator: Device programming that modifies AV timing</description>
        </group>
        <group group_id="E2">
          <title>Device Programming That Allows Intrinsic AV Timing.</title>
          <description>Cardiac resynchronization therapy-defibrillator: Device programming that does not modifies AV timing</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis induced cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged hospitalization due to sarcoidosis induced cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-sustained ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of patients analyzed. As the study was stopped early, the primary objective is underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elke Sommerijns</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+32479767156</phone>
      <email>elke.sommerijns@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

